JP7252888B2 - ジカウイルスエピトープに特異的に結合する新規抗体及びその使用 - Google Patents

ジカウイルスエピトープに特異的に結合する新規抗体及びその使用 Download PDF

Info

Publication number
JP7252888B2
JP7252888B2 JP2019501482A JP2019501482A JP7252888B2 JP 7252888 B2 JP7252888 B2 JP 7252888B2 JP 2019501482 A JP2019501482 A JP 2019501482A JP 2019501482 A JP2019501482 A JP 2019501482A JP 7252888 B2 JP7252888 B2 JP 7252888B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019501482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533425A (ja
JP2019533425A5 (OSRAM
Inventor
ダヴィデ・コルティ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Publication of JP2019533425A publication Critical patent/JP2019533425A/ja
Publication of JP2019533425A5 publication Critical patent/JP2019533425A5/ja
Priority to JP2023019144A priority Critical patent/JP2023062036A/ja
Application granted granted Critical
Publication of JP7252888B2 publication Critical patent/JP7252888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019501482A 2016-07-13 2017-07-12 ジカウイルスエピトープに特異的に結合する新規抗体及びその使用 Active JP7252888B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023019144A JP2023062036A (ja) 2016-07-13 2023-02-10 ジカウイルスエピトープに特異的に結合する新規抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2016/066684 WO2018010789A1 (en) 2016-07-13 2016-07-13 Novel antibodies specifically binding to zika virus epitopes and uses thereof
EPPCT/EP2016/066684 2016-07-13
PCT/EP2017/067581 WO2018011283A1 (en) 2016-07-13 2017-07-12 Novel antibodies specifically binding to zika virus epitopes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023019144A Division JP2023062036A (ja) 2016-07-13 2023-02-10 ジカウイルスエピトープに特異的に結合する新規抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2019533425A JP2019533425A (ja) 2019-11-21
JP2019533425A5 JP2019533425A5 (OSRAM) 2020-07-27
JP7252888B2 true JP7252888B2 (ja) 2023-04-05

Family

ID=56413654

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019501482A Active JP7252888B2 (ja) 2016-07-13 2017-07-12 ジカウイルスエピトープに特異的に結合する新規抗体及びその使用
JP2023019144A Pending JP2023062036A (ja) 2016-07-13 2023-02-10 ジカウイルスエピトープに特異的に結合する新規抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023019144A Pending JP2023062036A (ja) 2016-07-13 2023-02-10 ジカウイルスエピトープに特異的に結合する新規抗体及びその使用

Country Status (31)

Country Link
US (3) US11117954B2 (OSRAM)
EP (2) EP4342911A1 (OSRAM)
JP (2) JP7252888B2 (OSRAM)
KR (1) KR102595764B1 (OSRAM)
CN (2) CN109563157B (OSRAM)
AU (1) AU2017297757B2 (OSRAM)
BR (1) BR112018074456A2 (OSRAM)
CA (1) CA3024374A1 (OSRAM)
CL (2) CL2019000067A1 (OSRAM)
CO (1) CO2019001111A2 (OSRAM)
CR (1) CR20190066A (OSRAM)
DK (1) DK3484915T5 (OSRAM)
DO (2) DOP2019000006A (OSRAM)
EA (1) EA201990243A1 (OSRAM)
EC (1) ECSP19009170A (OSRAM)
ES (1) ES2959883T3 (OSRAM)
FI (1) FI3484915T3 (OSRAM)
HR (1) HRP20231196T1 (OSRAM)
HU (1) HUE063272T2 (OSRAM)
IL (1) IL262710B2 (OSRAM)
LT (1) LT3484915T (OSRAM)
MX (1) MX2019000526A (OSRAM)
MY (1) MY190553A (OSRAM)
PE (1) PE20190398A1 (OSRAM)
PH (1) PH12018502348B1 (OSRAM)
PL (1) PL3484915T3 (OSRAM)
SG (1) SG11201809879WA (OSRAM)
SI (1) SI3484915T1 (OSRAM)
UA (1) UA126381C2 (OSRAM)
WO (2) WO2018010789A1 (OSRAM)
ZA (1) ZA201807467B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6998935B2 (ja) 2016-07-13 2022-01-18 エボニック オペレーションズ ゲーエムベーハー 溶解された脂質含有バイオマスから脂質を分離する方法
CA3040189A1 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
EP3527664A1 (en) 2018-02-15 2019-08-21 Evonik Degussa GmbH Method of isolating lipids from a lipids containing biomass
JP2019152666A (ja) * 2018-03-02 2019-09-12 富士レビオ株式会社 ジカウイルスを検出する方法及びキット
US11884718B2 (en) 2018-04-24 2024-01-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination
WO2019219396A1 (en) 2018-05-15 2019-11-21 Evonik Operations Gmbh Method of isolating lipids from a lysed lipids containing biomass by emulsion inversion
DK3794097T3 (da) 2018-05-15 2024-12-16 Evonik Operations Gmbh Fremgangsmåde til isolering af lipider fra en lipid-indeholdende biomasse ved hjælp af hydrofob silica
WO2020061159A1 (en) * 2018-09-20 2020-03-26 Vanderbilt University Human antibodies to zika virus
WO2020078568A1 (en) * 2018-10-19 2020-04-23 Humabs Biomed Sa Antibodies and methods for treatment of lyssavirus infection
WO2020092564A1 (en) * 2018-10-31 2020-05-07 Icahn School Of Medicine At Mount Sinai Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof
US20220332800A1 (en) 2018-11-20 2022-10-20 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
WO2020245663A1 (en) * 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
US12570725B2 (en) * 2019-09-13 2026-03-10 Duke University ZIKA antibodies and their use
WO2021089055A1 (zh) * 2019-11-07 2021-05-14 中国科学院微生物研究所 一种寨卡/登革疫苗及其应用
US20230085393A1 (en) * 2019-11-19 2023-03-16 Vanderbilt University Human antibodies that neutralize zika virus and methods of use therefor
CN111138534B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 寨卡病毒囊膜蛋白的鼠源单克隆抗体
CN111100201B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体
JP7471555B2 (ja) * 2020-02-20 2024-04-22 国立感染症研究所長 フラビウイルス交差中和抗体及び医薬組成物
US20230324404A1 (en) 2020-05-20 2023-10-12 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
US20230204567A1 (en) 2020-05-20 2023-06-29 Takeda Vaccines, Inc. Method for determining the potency of antigens
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2022001803A1 (zh) * 2020-06-28 2022-01-06 神州细胞工程有限公司 一种降低病毒ade效应的方法
WO2022212858A2 (en) * 2021-04-01 2022-10-06 A2 Biotherapeutics, Inc. Polypeptides targeting hla-a*11 and methods of use thereof
CN112921124B (zh) * 2021-04-08 2021-09-28 广东创晟控股集团有限公司 一种快速检测病毒的试剂盒
WO2024211789A1 (en) * 2023-04-07 2024-10-10 Fred Hutchinson Cancer Center Cross-flavivirus binding domains and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
WO2004016586A2 (en) 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
DK2350128T3 (da) 2008-10-22 2014-12-01 Inst Research In Biomedicine Fremgangsmåder til fremstilling af antistoffer fra plasmaceller
SG11201507359SA (en) * 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Flavivirus neutralizing antibodies and methods of use thereof
CN109152828A (zh) 2016-03-11 2019-01-04 美国政府(由卫生和人类服务部的部长所代表) 减毒活zika病毒疫苗
WO2017181098A2 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
WO2019023468A1 (en) 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cell Host & Microbe,2016.05.11, Vol.19, pp.696-704

Also Published As

Publication number Publication date
IL262710B2 (en) 2024-05-01
DOP2019000006A (es) 2019-03-31
EP3484915B1 (en) 2023-08-16
IL262710B1 (en) 2024-01-01
AU2017297757A1 (en) 2018-11-22
US20190256582A1 (en) 2019-08-22
EP4342911A1 (en) 2024-03-27
BR112018074456A2 (pt) 2019-03-19
SI3484915T1 (sl) 2024-02-29
ECSP19009170A (es) 2019-02-28
JP2019533425A (ja) 2019-11-21
DK3484915T3 (da) 2023-10-09
CN109563157A (zh) 2019-04-02
PH12018502348A1 (en) 2019-03-25
SG11201809879WA (en) 2018-12-28
KR102595764B1 (ko) 2023-10-30
PE20190398A1 (es) 2019-03-13
US20210363227A1 (en) 2021-11-25
CL2019000067A1 (es) 2019-07-26
CN116199775A (zh) 2023-06-02
WO2018010789A1 (en) 2018-01-18
UA126381C2 (uk) 2022-09-28
CR20190066A (es) 2019-09-10
WO2018011283A1 (en) 2018-01-18
MY190553A (en) 2022-04-27
MX2019000526A (es) 2019-05-02
PL3484915T3 (pl) 2024-03-25
AU2017297757B2 (en) 2024-06-13
KR20190027382A (ko) 2019-03-14
JP2023062036A (ja) 2023-05-02
DOP2021000026A (es) 2021-07-30
ZA201807467B (en) 2024-04-24
DK3484915T5 (da) 2024-09-02
CO2019001111A2 (es) 2019-08-20
CL2021002994A1 (es) 2022-09-09
LT3484915T (lt) 2023-10-10
HUE063272T2 (hu) 2024-01-28
US11912757B2 (en) 2024-02-27
FI3484915T3 (fi) 2023-11-15
CN109563157B (zh) 2023-01-17
IL262710A (en) 2018-12-31
CA3024374A1 (en) 2018-01-18
US20210355198A1 (en) 2021-11-18
PH12018502348B1 (en) 2024-02-28
HRP20231196T1 (hr) 2024-01-19
EA201990243A1 (ru) 2019-07-31
US11117954B2 (en) 2021-09-14
EP3484915A1 (en) 2019-05-22
ES2959883T3 (es) 2024-02-28

Similar Documents

Publication Publication Date Title
US11912757B2 (en) Antibodies specifically binding to Zika virus epitopes and uses thereof
US20240254207A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
JP2023518849A (ja) 重症急性呼吸器症候群コロナウイルス２（ＳＡＲＳ－ＣｏＶ－２）に対するヒトモノクローナル抗体
BR122024006890A2 (pt) Anticorpo isolado, ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, vetor, célula, composição farmacêutica, uso dos mesmos, kit de partes, bem como ensaio de bloqueio de ligação para diagóstico in vitro de infecção por zika vírus
HK40002097B (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
HK40002097A (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
EA046175B1 (ru) Выделенное антитело или его антигенсвязывающий фрагмент, которые специфически связываются с эпитопом вируса зика, их получение и применения
HK40025147B (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
HK40025147A (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
HK40006233B (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
RU2803850C2 (ru) Нейтрализующие антитела к вирусу гриппа а и пути их применения
HK40006233A (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
EA043940B1 (ru) Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение
EP4259654A1 (en) Antibodies binding to f-protein of metapneumovirus and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230210

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230210

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230216

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230324

R150 Certificate of patent or registration of utility model

Ref document number: 7252888

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150